Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Biol Chem. 2010 Apr;391(4):333-43. doi: 10.1515/BC.2010.044.

Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer.

Author information

  • 1Department of Pharmacology and Molecular Science, The Johns Hopkins University School of Medicine, Baltimore, MD 2131, USA. Aaron.Lebeau@ucsf.edu

Abstract

The role of prostate-specific antigen (PSA) or kallikrein-related peptidase 3 (KLK3) as a biomarker for prostate cancer is well known; however, the precise physiological role of it's serine protease activity in prostate cancer remains a mystery. PSA is produced at high levels by both androgen-dependent and -independent prostate cancers. Studies have documented high levels of active PSA in the milieu surrounding osseous and soft tissue metastases. This evidence, coupled with growing experimental evidence, suggests that PSA plays an important role in the pathobiology of prostate cancer. These observations support the development of PSA-selective inhibitors as useful tools for the targeted treatment and imaging of prostate cancer. Here, we review the research that has been conducted to date on developing selective inhibitors for PSA. The different approaches used to determine PSA substrate specificity and for creating inhibitors are discussed. In addition, the unique active site characteristics of PSA and how these motifs aided our research in developing PSA targeted agents are highlighted.

PMID:
20180648
[PubMed - indexed for MEDLINE]
PMCID:
PMC3454521
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Figure 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for iFactory Icon for PubMed Central
    Loading ...
    Write to the Help Desk